Paul Workman (scientist): Difference between revisions

From Wikipedia, the free encyclopedia
Content deleted Content added
URL removed. See talk page for more info.
Adding/improving reference(s)
Line 29: Line 29:
}}
}}


'''Paul Workman''', {{Post-nominals|country=GBR|FRS|FRSC|FMedSci|size=100%|sep=,}} (born 30 March 1952) is a British scientist.
'''Paul Workman''', {{Post-nominals|country=GBR|FRS|FRSC|FMedSci|size=100%|sep=,}} (born 30 March 1952) is a British scientist noted for his work on the discovery and development of pharmaceutical agents in the field of [[oncology]].<ref>{{cite journal|last1=Workman|first1=Paul|title=Introduction|journal=New Approaches in Cancer Pharmacology: Drug Design and Development|date=1994|pages=1–4|doi=10.1007/978-3-642-79088-1_1|url=https://doi.org/10.1007/978-3-642-79088-1_1|publisher=Springer, Berlin, Heidelberg|language=en}}</ref>


==Education and early life==
==Education and early life==
Line 40: Line 40:
In 1990 Workman spent a sabbatical period in the Department of Therapeutic Radiology, [[Stanford University]] and SRI International, California, USA where he continued his work on tumour hypoxia funded by a Fellowship from what was then the [[International Union Against Cancer]].
In 1990 Workman spent a sabbatical period in the Department of Therapeutic Radiology, [[Stanford University]] and SRI International, California, USA where he continued his work on tumour hypoxia funded by a Fellowship from what was then the [[International Union Against Cancer]].


In 1991 Workman was appointed as a Cancer Research Campaign (CRC) Life Fellow, Professor of Experimental Cancer Therapy, University of Glasgow and Director of Laboratory Research in the CRC Department of Medical Oncology, CRC Beatson Laboratories, Glasgow.<ref>{{cite journal |title=Paul Workman moves to Glasgow|url=http://annonc.oxfordjournals.org/content/2/5/314.full.pdf |journal=Annals of Oncology News |publisher=[[Annals of Oncology]] |date=1991 | volume=2 |issue=5 |pages= 314–319 |accessdate=8 July 2014 }}</ref> Here he extended his research on tumour hypoxia and molecular targeted therapies. Workman also continued his service for the European Organisation for Research and Treatment of Cancer (EORTC) as Chairman of the EORTC Pharmacology and Molecular Mechanisms Group. Member of EORTC Board and Council as Chairman of the EORTC New Drug Development Coordinating Committee.<ref>{{cite journal |url=http://cancerres.aacrjournals.org/content/48/11/3297.full.pdf |title=Cancer Research announcements |journal=Cancer Research |date=1988 |volume=48 |pages=3297–3298. |accessdate=8 July 2014 }}</ref><ref>{{cite journal |url=http://annonc.oxfordjournals.org/content/5/suppl_5/7.full.pdf |title=History of NCI-EORTC collaboration |publisher=Annals of Oncology |date=1994 |volume= 5 (suppl 5) |pages=7–16 |accessdate=8 July 2014 }}</ref>
In 1991 Workman was appointed as a Cancer Research Campaign (CRC) Life Fellow, Professor of Experimental Cancer Therapy, University of Glasgow and Director of Laboratory Research in the CRC Department of Medical Oncology, CRC Beatson Laboratories, Glasgow.<ref>{{cite journal |title=Paul Workman moves to Glasgow|url=http://annonc.oxfordjournals.org/content/2/5/314.full.pdf |journal=Annals of Oncology News |publisher=[[Annals of Oncology]] |date=1991 | volume=2 |issue=5 |pages= 314–319 |accessdate=8 July 2014 }}</ref> Here he extended his research on tumour hypoxia and molecular targeted therapies.<ref>{{cite journal|last1=Chau|first1=Noan-Minh|last2=Rogers|first2=Paul|last3=Aherne|first3=Wynne|last4=Carroll|first4=Veronica|last5=Collins|first5=Ian|last6=McDonald|first6=Edward|last7=Workman|first7=Paul|last8=Ashcroft|first8=Margaret|title=Identification of Novel Small Molecule Inhibitors of Hypoxia-Inducible Factor-1 That Differentially Block Hypoxia-Inducible Factor-1 Activity and Hypoxia-Inducible Factor-1α Induction in Response to Hypoxic Stress and Growth Factors|journal=Cancer Research|date=1 June 2005|volume=65|issue=11|pages=4918–4928|doi=10.1158/0008-5472.CAN-04-4453|url=https://doi.org/10.1158/0008-5472.can-04-4453|language=en|issn=0008-5472}}</ref><ref>{{cite book|last1=Workman|first1=Paul|title=Cancer Chemoprevention|date=2004|doi=10.1007/978-1-59259-767-3_22|publisher=Humana Press, Totowa, NJ|isbn=9781617373428|pages=325–337|url=https://doi.org/10.1007/978-1-59259-767-3_22|language=en|chapter=Pharmacological Intervention With Multistep Oncogenesis}}</ref><ref>{{cite book|last1=Workman|first1=Paul|title=Principles of Molecular Oncology|pages=421–438|url=http://www.worldcat.org/oclc/890636199|chapter=Emerging Molecular Therapies: Small-Molecule Drugs}}</ref> Workman also continued his service for the European Organisation for Research and Treatment of Cancer (EORTC) as Chairman of the EORTC Pharmacology and Molecular Mechanisms Group. Member of EORTC Board and Council as Chairman of the EORTC New Drug Development Coordinating Committee.<ref>{{cite journal |url=http://cancerres.aacrjournals.org/content/48/11/3297.full.pdf |title=Cancer Research announcements |journal=Cancer Research |date=1988 |volume=48 |pages=3297–3298. |accessdate=8 July 2014 }}</ref><ref>{{cite journal |url=http://annonc.oxfordjournals.org/content/5/suppl_5/7.full.pdf |title=History of NCI-EORTC collaboration |publisher=Annals of Oncology |date=1994 |volume= 5 (suppl 5) |pages=7–16 |accessdate=8 July 2014 }}</ref>


Workman joined the [[Institute of Cancer Research|ICR]] in 1997 to develop its [[Cancer Research UK]] Cancer Therapeutics Unit.<ref name="autogenerated2"/> Workman's team collaborates with The [[Royal Marsden]] to bring new treatments to patients through [[clinical trials]].<ref>{{Cite web |url=http://www.royalmarsden.nhs.uk/research/pages/partnership.aspx |title=Partners |publisher=The Royal Marsden and The Institute of Cancer Research |accessdate=4 April 2012 }}</ref> Overall, since 2005, the Cancer Therapeutic Unit has discovered 17 drug candidates, seven of which have progressed to the patient trial stage. Workman has attributed this record to "taking early academic risks, combining academic and pharmaceutical expertise, and implementing strong leadership and project management. Other contributing factors include running multiple projects on a competitive scale, establishing long-term financial support and – most important – selecting productive and timely industrial collaborations."<ref>{{cite journal |url=http://www.nature.com/nature/journal/v510/n7504/full/510218d.html |title=Academia and industry: Successes for UK cancer partnership |journal=Nature |date=11 June 2014 |accessdate=24 June 2014 |volume=510 |doi=10.1038/510218d |page=218}}</ref>
Workman joined the [[Institute of Cancer Research|ICR]] in 1997 to develop its [[Cancer Research UK]] Cancer Therapeutics Unit.<ref name="autogenerated2"/> Workman's team collaborated with The [[Royal Marsden]] to bring new treatments to patients through [[clinical trials]].<ref>{{Cite web |url=http://www.royalmarsden.nhs.uk/research/pages/partnership.aspx |title=Partners |publisher=The Royal Marsden and The Institute of Cancer Research |accessdate=4 April 2012 }}</ref> Overall, since 2005, the Cancer Therapeutic Unit has discovered 17 drug candidates, seven of which have progressed to the patient trial stage. Workman has attributed this record to "taking early academic risks, combining academic and pharmaceutical expertise, and implementing strong leadership and project management. Other contributing factors include running multiple projects on a competitive scale, establishing long-term financial support and – most important – selecting productive and timely industrial collaborations."<ref>{{cite journal |url=http://www.nature.com/nature/journal/v510/n7504/full/510218d.html |title=Academia and industry: Successes for UK cancer partnership |journal=Nature |date=11 June 2014 |accessdate=24 June 2014 |volume=510 |doi=10.1038/510218d |page=218}}</ref>


Workman was appointed Deputy CEO of the [[Institute of Cancer Research|ICR]] in March 2011.<ref name="autogenerated2">{{cite web |url=http://www.icr.ac.uk/research/team_leaders/Workman_Paul/index.shtml |title=Professor Paul Workman |publisher=Icr.ac.uk |date= |accessdate=4 April 2012 }}</ref>
Workman was appointed Deputy CEO of the [[Institute of Cancer Research|ICR]] in March 2011.<ref name="autogenerated2">{{cite web |url=http://www.icr.ac.uk/research/team_leaders/Workman_Paul/index.shtml |title=Professor Paul Workman |publisher=Icr.ac.uk |date= |accessdate=4 April 2012 }}</ref>
Line 48: Line 48:
Research on [[Phosphoinositide 3-kinase inhibitor]]s, led by Workman and Dr. Florence Raynaud at the ICR, was selected as one of 16 studies to have had the greatest impact on patients, according to the American Association of Cancer Research journal Molecular Cancer Therapeutics.<ref>{{cite web |url=http://www.icr.ac.uk/press/recent_featured_articles/Workman_Conference/index.shtml |title=ICR drug discovery highlighted for patient impact |publisher=Icr.ac.uk |date=11 November 2011 |accessdate=4 April 2012 }}</ref>
Research on [[Phosphoinositide 3-kinase inhibitor]]s, led by Workman and Dr. Florence Raynaud at the ICR, was selected as one of 16 studies to have had the greatest impact on patients, according to the American Association of Cancer Research journal Molecular Cancer Therapeutics.<ref>{{cite web |url=http://www.icr.ac.uk/press/recent_featured_articles/Workman_Conference/index.shtml |title=ICR drug discovery highlighted for patient impact |publisher=Icr.ac.uk |date=11 November 2011 |accessdate=4 April 2012 }}</ref>


Workman is currently working on drugs that block molecules essential for the growth and survival of [[cancer cell]]s, in particular, molecular chaperones such as [[Hsp90]].<ref>{{cite web |url=http://ecancer.org/tv/pubdate/773 |title=SABCS 2010: Molecular chaperones: cancer dependence and druggability – Prof Paul Workman – The Institute of Cancer Research, Sutton, UK |publisher=Ecancer.org |date= |accessdate=4 April 2012 }}</ref> The leading Hsp90 inhibitor was discovered by Workman's team at ICR in collaboration with Vernalis.<ref>{{cite journal |journal =Cancer Research |date= 15 April 2008 |pmid=18413753 | doi=10.1158/0008-5472.CAN-07-5256 |volume=68 |issue=8 |title=NVP-AUY922: a novel heat shock protein 90 inhibitor active against xenograft tumor growth, angiogenesis, and metastasis |pages=2850–60 | last1 = Eccles | first1 = SA | last2 = Massey | first2 = A | last3 = Raynaud | first3 = FI | display-authors = 3 | last4 = et al}}</ref>
Workman is currently working on drugs that block molecules essential for the growth and survival of [[cancer cell]]s, in particular, molecular chaperones such as [[Hsp90]].<ref>{{cite book|last1=Powers|first1=Marissa V.|last2=Workman|first2=Paul|title=Encyclopedia of Cancer|date=2015|doi=10.1007/978-3-662-46875-3_3810|chapter-url=https://doi.org/10.1007/978-3-662-46875-3_3810|publisher=Springer, Berlin, Heidelberg|pages=2894–2898|url=https://doi.org/10.1007/978-3-662-46875-3_3810|language=en|chapter=Molecular Chaperones}}</ref><ref>{{cite journal|last1=Workman|first1=Paul|title=Preface [Hot topic:Hsp90 Molecular Chaperone Inhibitors: Opportunities and Challenges (Guest Editor: Paul Workman)]|journal=Current Cancer Drug Targets|date=30 September 2003|volume=3|issue=5|doi=10.2174/1568009033481840|url=https://doi.org/10.2174/1568009033481840|language=en}}</ref><ref>{{cite web |url=http://ecancer.org/tv/pubdate/773 |title=SABCS 2010: Molecular chaperones: cancer dependence and druggability – Prof Paul Workman – The Institute of Cancer Research, Sutton, UK |publisher=Ecancer.org |date= |accessdate=4 April 2012 }}</ref> The leading Hsp90 inhibitor was discovered by Workman's team at ICR in collaboration with Vernalis.<ref>{{cite journal |journal =Cancer Research |date= 15 April 2008 |pmid=18413753 | doi=10.1158/0008-5472.CAN-07-5256 |volume=68 |issue=8 |title=NVP-AUY922: a novel heat shock protein 90 inhibitor active against xenograft tumor growth, angiogenesis, and metastasis |pages=2850–60 | last1 = Eccles | first1 = SA | last2 = Massey | first2 = A | last3 = Raynaud | first3 = FI | display-authors = 3 | last4 = et al}}</ref>


===Awards and honours===
===Awards and honours===

Revision as of 13:17, 10 February 2018

Paul Workman
Paul Workman at the Royal Society admissions day in London, July 2016
Born (1952-03-30) 30 March 1952 (age 72)
NationalityBritish
Alma mater
Known forCancer drugs
Awards
Scientific career
Institutions
ThesisStudies on some enzyme-activated anti-tumour agents (1976)
Websitewww.icr.ac.uk/our-research/researchers-and-teams/professor-paul-workman

Paul Workman, FRS, FRSC, FMedSci (born 30 March 1952) is a British scientist noted for his work on the discovery and development of pharmaceutical agents in the field of oncology.[1]

Education and early life

Paul Workman

Workman was born on 30 March 1952 in Workington, Cumbria, England.[2] He was educated at Workington County Grammar School, Cumbria, and completed his BSc degree in Biochemistry at the University of Leicester and his PhD degree in Cancer Pharmacology at the University of Leeds. He later received an Honorary DSc degree from the University of Leicester in 2009.

Career and research

The early part of his career (1976–90) was spent establishing and leading the Pharmacology and New Drug Development Laboratory at the Medical Research Council's Clinical Oncology Unit at the University of Cambridge, where he developed new treatments to exploit hypoxic cells in solid tumours and elucidated the enzymes involved in the activation of hypoxia-targeted drugs.[3]

In 1990 Workman spent a sabbatical period in the Department of Therapeutic Radiology, Stanford University and SRI International, California, USA where he continued his work on tumour hypoxia funded by a Fellowship from what was then the International Union Against Cancer.

In 1991 Workman was appointed as a Cancer Research Campaign (CRC) Life Fellow, Professor of Experimental Cancer Therapy, University of Glasgow and Director of Laboratory Research in the CRC Department of Medical Oncology, CRC Beatson Laboratories, Glasgow.[4] Here he extended his research on tumour hypoxia and molecular targeted therapies.[5][6][7] Workman also continued his service for the European Organisation for Research and Treatment of Cancer (EORTC) as Chairman of the EORTC Pharmacology and Molecular Mechanisms Group. Member of EORTC Board and Council as Chairman of the EORTC New Drug Development Coordinating Committee.[8][9]

Workman joined the ICR in 1997 to develop its Cancer Research UK Cancer Therapeutics Unit.[3] Workman's team collaborated with The Royal Marsden to bring new treatments to patients through clinical trials.[10] Overall, since 2005, the Cancer Therapeutic Unit has discovered 17 drug candidates, seven of which have progressed to the patient trial stage. Workman has attributed this record to "taking early academic risks, combining academic and pharmaceutical expertise, and implementing strong leadership and project management. Other contributing factors include running multiple projects on a competitive scale, establishing long-term financial support and – most important – selecting productive and timely industrial collaborations."[11]

Workman was appointed Deputy CEO of the ICR in March 2011.[3]

Research on Phosphoinositide 3-kinase inhibitors, led by Workman and Dr. Florence Raynaud at the ICR, was selected as one of 16 studies to have had the greatest impact on patients, according to the American Association of Cancer Research journal Molecular Cancer Therapeutics.[12]

Workman is currently working on drugs that block molecules essential for the growth and survival of cancer cells, in particular, molecular chaperones such as Hsp90.[13][14][15] The leading Hsp90 inhibitor was discovered by Workman's team at ICR in collaboration with Vernalis.[16]

Awards and honours

References

  1. ^ Workman, Paul (1994). "Introduction". New Approaches in Cancer Pharmacology: Drug Design and Development. Springer, Berlin, Heidelberg: 1–4. doi:10.1007/978-3-642-79088-1_1.
  2. ^ "WORKMAN, Prof. Paul". Who's Who 2016. Oxford University Press. November 2015. Retrieved 14 October 2016.
  3. ^ a b c "Professor Paul Workman". Icr.ac.uk. Retrieved 4 April 2012.
  4. ^ "Paul Workman moves to Glasgow" (PDF). Annals of Oncology News. 2 (5). Annals of Oncology: 314–319. 1991. Retrieved 8 July 2014.
  5. ^ Chau, Noan-Minh; Rogers, Paul; Aherne, Wynne; Carroll, Veronica; Collins, Ian; McDonald, Edward; Workman, Paul; Ashcroft, Margaret (1 June 2005). "Identification of Novel Small Molecule Inhibitors of Hypoxia-Inducible Factor-1 That Differentially Block Hypoxia-Inducible Factor-1 Activity and Hypoxia-Inducible Factor-1α Induction in Response to Hypoxic Stress and Growth Factors". Cancer Research. 65 (11): 4918–4928. doi:10.1158/0008-5472.CAN-04-4453. ISSN 0008-5472.
  6. ^ Workman, Paul (2004). "Pharmacological Intervention With Multistep Oncogenesis". Cancer Chemoprevention. Humana Press, Totowa, NJ. pp. 325–337. doi:10.1007/978-1-59259-767-3_22. ISBN 9781617373428.
  7. ^ Workman, Paul. "Emerging Molecular Therapies: Small-Molecule Drugs". Principles of Molecular Oncology. pp. 421–438.
  8. ^ "Cancer Research announcements" (PDF). Cancer Research. 48: 3297–3298. 1988. Retrieved 8 July 2014.
  9. ^ "History of NCI-EORTC collaboration" (PDF). 5 (suppl 5). Annals of Oncology. 1994: 7–16. Retrieved 8 July 2014. {{cite journal}}: Cite journal requires |journal= (help)
  10. ^ "Partners". The Royal Marsden and The Institute of Cancer Research. Retrieved 4 April 2012.
  11. ^ "Academia and industry: Successes for UK cancer partnership". Nature. 510: 218. 11 June 2014. doi:10.1038/510218d. Retrieved 24 June 2014.
  12. ^ "ICR drug discovery highlighted for patient impact". Icr.ac.uk. 11 November 2011. Retrieved 4 April 2012.
  13. ^ Powers, Marissa V.; Workman, Paul (2015). "Molecular Chaperones". Encyclopedia of Cancer. Springer, Berlin, Heidelberg. pp. 2894–2898. doi:10.1007/978-3-662-46875-3_3810.
  14. ^ Workman, Paul (30 September 2003). "Preface [Hot topic:Hsp90 Molecular Chaperone Inhibitors: Opportunities and Challenges (Guest Editor: Paul Workman)]". Current Cancer Drug Targets. 3 (5). doi:10.2174/1568009033481840.
  15. ^ "SABCS 2010: Molecular chaperones: cancer dependence and druggability – Prof Paul Workman – The Institute of Cancer Research, Sutton, UK". Ecancer.org. Retrieved 4 April 2012.
  16. ^ Eccles, SA; Massey, A; Raynaud, FI; et al. (15 April 2008). "NVP-AUY922: a novel heat shock protein 90 inhibitor active against xenograft tumor growth, angiogenesis, and metastasis". Cancer Research. 68 (8): 2850–60. doi:10.1158/0008-5472.CAN-07-5256. PMID 18413753. {{cite journal}}: Explicit use of et al. in: |last4= (help)
  17. ^ "Cancer Drug Researcher Receives Royal Society of Chemistry Award – ICR Global Foundation". Icrgf.org. 4 June 2010. Retrieved 4 April 2012.
  18. ^ "Oncology: Pierre Fabre sponsors the Bourgine Prize". Pierre Fabre. 2 June 2014. Retrieved 24 June 2014.
  19. ^ "Fellows Directory". European Academy of Cancer Sciences. 12 May 2014. Retrieved 24 June 2012.